Company Movements - Aimei Health Technology Co., Ltd (NASDAQ:AFJK) saw its stock price surge to $32.04, marking a 300.5% increase, with trading volume exceeding 5.3 million shares, indicating strong investor interest driven by optimism around its strategic direction in the biopharmaceutical and medical technology sectors [1][6] - Thrivent High Yield S (LBHIX) experienced a price increase to $17.16, a 299.24% rise, reflecting a potential shift in investor sentiment towards high-yield investments amidst market volatility [2][6] - Oriental Culture Holding Ltd. (NASDAQ:OCG) had its stock price rise to $8.25, a 214.89% increase, attributed to investor enthusiasm for its ventures into NFTs and metaverse projects, alongside a significant increase in trading volume [3][6] - Polestar Automotive Holding UK PLC (NASDAQ:PSNYW) faced a price drop to $4.5, a 26.36% decrease, which may be linked to market corrections or broader industry trends affecting electric vehicle manufacturers [4][6] Market Dynamics - The recent price movements of these companies highlight the dynamic nature of the stock market, influenced by company-specific developments, investor sentiment, and broader economic factors [5][6]

Led by insiders, including Perimeter's CEO Adrian Mendes This press release shall not constitute an offer to sell or the solicitation of an offer to buy nor shall there be any sale of the securities in any jurisdiction in which such offer, solicitation or sale would be unlawful. The securities being offered have not been, nor will they be, registered under the United States Securities Act of 1933, as amended (the "1933 Act") and may not be offered or sold in the United States or to, or for the account or be ...

Not for distribution to United States newswire services or for dissemination in the United States. BROSSARD, Quebec, Dec. 09, 2025 (GLOBE NEWSWIRE) -- Diagnos Inc. (“DIAGNOS” or the “Company”) (TSXV: ADK and OTCQB: DGNOF) is pleased to announce the successful closing of its previously announced upsized private placement (the “Offering”) of units of the Company (the “Units”). A total of 13,337,262 Units, including pursuant to an exercise of the over-allotment option, were sold under the Offering at a price o ...

Core Viewpoint - Broadwood Partners, which owns 30.2% of STAAR Surgical Company, opposes the proposed acquisition by Alcon Inc., claiming the sale process was flawed and the offered price inadequate [1][6]. Group 1: Sale Process and Board Actions - The STAAR Board is accused of running a flawed sale process, ignoring buyout interest from multiple parties, and negotiating exclusively with Alcon, with whom the Chair had a prior relationship [3][4]. - Shareholders were prepared to reject the transaction, but the Board postponed the vote multiple times and attempted to implement a go-shop mechanism that failed to attract competitive bids [4][5]. - The Board's claims regarding the fairness of the sale process and the compensation packages for executives have been challenged, with Broadwood asserting that these claims were misleading [2][5]. Group 2: Financial Aspects and Shareholder Concerns - Alcon's initial offer of $28 per share was criticized as inadequate, especially after it later increased the offer by $150 million due to shareholder pressure [5][6]. - Concerns were raised about the substantial financial incentives for STAAR's executives, particularly the CEO's potential $24 million payout for a short tenure, which could compromise the integrity of the sale process [5][6]. - Broadwood believes that STAAR's true value exceeds $30.75 per share, suggesting that a properly structured competitive process could yield a higher offer from Alcon [7]. Group 3: Future Outlook and Shareholder Actions - Broadwood expresses confidence in STAAR's future as an independent company, anticipating it could become one of the most profitable medical technology firms if management's projections are met [7]. - Broadwood intends to vote against the revised transaction and encourages other shareholders to do the same, emphasizing the need for a more credible Board to maximize shareholder value [8].

Group 1 - Alcon has increased its acquisition bid for Staar Surgical to $30.75 per share in cash [1] - The total valuation of Staar Surgical is now at $1.6 billion [1]

Group 1 - Theta Gold Mines (ASX: TGM) has completed the procurement of key long-cycle processing equipment for its TGME gold project, ensuring the project continues to progress as planned [4] - The company has signed equipment orders with South African metallurgical engineering firms Kemix and MIP Industries, covering essential equipment such as mixers, electro-winning circuits, thickeners, flocculant systems, and control instruments [4] - Installation and delivery schedules for these facilities have been established, with suppliers also participating in equipment commissioning and providing on-site training to ensure smooth production [4] Group 2 - The current earthworks and civil engineering progress is stable, with cost control remaining within budget, moving closer to the target of commencing production by the end of 2026 [4] - The project is expected to create over 500 jobs locally, injecting significant economic vitality into the area upon full production [4] - Bill Guy, Executive Chairman, emphasized that the finalization of key equipment marks an important milestone for the TGME project, which is progressing steadily in both mechanical and civil engineering aspects [4] Group 3 - National Storage REIT (ASX: NSR) has signed a scheme implementation agreement with a consortium led by Brookfield and GIC to acquire all issued securities at a cash price of AUD 2.86 per stapled security [16] - The transaction implies an equity value of approximately AUD 4 billion, representing a premium of about 26.5% over NSR's closing price and a premium of approximately 10.9% over net tangible assets [17] - The board unanimously supports the transaction, indicating it reflects recognition of the high-quality, growth-potential assets within NSR's portfolio [17] Group 4 - Vulcan Energy Resources Ltd (ASX: VUL) has launched an AUD 1.1 billion equity financing plan, following the completion of an AUD 710 million institutional placement and entitlement offer [19] - The company has secured strategic financing support worth EUR 2.2 billion (AUD 3.9 billion) from various European and international government-related entities to accelerate the development of its Lionheart lithium and renewable energy project [20] - The Lionheart project aims to produce 24,000 tons of lithium hydroxide monohydrate annually, sufficient for manufacturing 500,000 electric vehicle batteries each year [21]

Core Insights - Medtronic is planning to spin out its diabetes unit, MiniMed, into a standalone company by the end of 2026, with an initial public offering as the preferred method for separation [3][9] - The company has appointed Ryan Weispfenning to lead the investor relations function at MiniMed, leveraging his 17 years of experience in Medtronic's investor relations team [4][5][9] - Ingrid Goldberg has been hired as the new vice president and head of investor relations at Medtronic, previously holding a similar role at Novocure [6][9] Group 1 - Medtronic's separation of its diabetes unit is on track for completion by the end of 2026 [3] - The company aims for MiniMed to become an independent, publicly traded entity [5] - Weispfenning's strong relationships with analysts and investors are expected to be beneficial for MiniMed's transition [5] Group 2 - Goldberg's background includes significant experience in medtech investor relations, having worked at Abiomed and Bluebird Bio [7][9] - The leadership change in investor relations is part of Medtronic's strategy to prepare for the spin-off of its diabetes division [9]

Core Insights - RetinalGenix Technologies Inc. has appointed M. Cory Zwerling as chief financial officer and interim chief operating officer, effective January 1, 2026, to guide the company through its commercial launch [1][2] Group 1: Leadership and Experience - Mr. Zwerling brings over 30 years of experience in healthcare, finance, and operations, particularly in pharmaceuticals, medical imaging, biotechnology, and digital health [1][2] - His background includes leadership roles in global pharmaceutical and imaging divisions, founding a healthcare IT/AI company, and serving as CEO of a medical-device venture, aligning with RetinalGenix's transition from R&D to commercial operations [3] Group 2: Company Strategy and Technology - RetinalGenix is focused on revolutionizing early disease detection and improving patient outcomes through the integration of genetic screening, advanced imaging, and therapeutic development [4] - The company is developing proprietary technologies aimed at preventing blindness and detecting physiological changes indicative of various diseases, including neurodegenerative and cardiovascular conditions [4]

Core Thesis - TransMedics Group, Inc. (TMDX) is viewed positively due to its strong revenue growth, operational efficiencies, and potential for international expansion, despite a recent minor revenue miss leading to initial stock volatility [1][2][5]. Financial Performance - TMDX reported Q3 2025 revenue of $143.8 million, reflecting a 32% year-over-year growth, marking the 15th consecutive quarter of over 30% growth [2][3]. - The company experienced a significant increase in operating income, which surged nearly fivefold to $23.3 million, resulting in a 16.2% operating margin [3]. - Gross margins expanded by 290 basis points to 59%, driven by operational efficiencies and fleet optimization [3]. Market Expansion - International sales are currently modest at $3.6 million, but TMDX is preparing for expansion with the National Organ Care System Program set to launch in Italy in the first half of 2026, aiming for broader European engagement by FY27 [3][4]. - The upcoming Gen 3 Organ Care System platform and the 2027 launch of the kidney program are expected to significantly increase the addressable market [4]. Valuation and Investment Case - TMDX's forward revenue multiple stands at 6.8x, which is considerably lower than peers, indicating it may be undervalued relative to recent sector acquisitions [5]. - The company's operational momentum, expanding competitive moat, and multi-year growth visibility support a strong long-term investment case [5][6].

MESA, ARIZONA / ACCESS Newswire / December 8, 2025 / Medical Care Technologies Inc. (OTC Pink:MDCE) is thrilled to announce a major technology advancement in the development of its soon-to-launch AI wound and skin monitoring platform. The Company has strategically aligned with Derm Foundation, a Google-backed pretrained dermatology imaging model, enabling the app to rapidly evolve into one of the most accessible early-warning tools for melanoma, infection risks, and chronic wound deterioration directly from ...